AZD2014,
AZD2014,
1009298-59-2,
Vistusertib,
AZD-2014,
AZD 2014,
UNII-0BSC3P4H5X,
vistusertib (AZD2014),
0BSC3P4H5X,
cc-551,
3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide,
CHEMBL2336325,
3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide,
C25H30N6O3,
3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide,
3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide,
Benzamide, 3-(2,4-bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl-,
Vistusertib [INN],
Benzamide, 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methyl-,
Vistusertib [USAN],
Vistusertib (JAN/INN),
MLS006011011,
SCHEMBL290672,
GTPL7699,
AOB3574,
DTXSID20143584,
EX-A155,
SYN1167,
BCP05748,
KS-000000YA,
BDBM50429701,
MFCD22628784,
s2783,
ZINC59258964,
AKOS024464879,
BCP9000362,
CS-0701,
DB11925,
QC-4554,
SB16565,
NCGC00346698-11,
4CA-0223,
AC-28425,
AS-16302,
BC600520,
HY-15247,
SC-62590,
SMR004702809,
AB0095803,
SW219704-1,
X3569,
D10887,
W-5962,
J-000268,
3-[2,4-Bis-[(3S)-3-methyl-4-morpholinyl]-pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide,
D0Z2UQ,
A8373,
Vistusertib, 98%, a novel mTOR inhibitor - 100MG 100mg,